We revisit Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to partners Jazz ...
Johnson & Johnson shares have underperformed for years, with multiple contributing causes including upcoming generic competition for Stelara, uncertainty around talc litigation, and questions about ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback